Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Evotec SE
Private Company Edition: Iambic, formerly known as Entos, closed a $100m series B venture capital round to advance its AI-discovered therapeutics. Also, Evozyne raised $81m and Acesion brought in €45m in series B rounds, while Mogrify added $10m to bring its series A to $46m.
In a wilderness period for biotech stocks, platform company revenues may offer investors less volatile biotech exposure. They are unlikely to shepherd an exit from the current doldrums, though.
Andrew Hopkins, founder and CEO of Exscientia, invented and championed an algorithmic approach to drug design and drug discovery. He talks to In Vivo about artificial intelligence in the biopharma industry today and what lies ahead.
In the aftermath of announcing a major collaboration with Sandoz on biosimilars, Evotec’s chief business officer Matthias Evers speaks about how the deal provides “validation” of Just-Evotec’s technology platform, while also outlining the firm’s wider ambitions to enable more efficient development of and broader access to biologics.
- Drug Discovery Tools
- Gene Therapy, Cell Therapy
Drug Discovery Tools
- Other Names / Subsidiaries
- Bionamics GmbH
- Cyprotex PLC
- DeveloGen AG
- Euprotec Ltd
- Evotec AG
- Evotec BioSystems GmbH
- Evotec Neurosciences GmbH
- Evotec BioSystems AG
- Just Biotherapeutics, Inc.
- Kinaxo Biotechnologies
- Compound Focus
- Just – Evotec Biologics, Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.